Literature DB >> 11016309

Influence of concomitant CABG and urgent/emergent status on mitral valve replacement surgery.

V H Thourani1, W S Weintraub, J M Craver, E L Jones, J P Gott, W M Brown, J D Puskas, R A Guyton.   

Abstract

BACKGROUND: Outcomes and resource utilization of patients undergoing mitral valve replacement (MVR) with or without concomitant coronary artery bypass grafting (CABG) were reviewed.
METHODS: Data for 1,844 patients undergoing isolated primary MVR at Emory University Hospitals between 1980 and 1997 were recorded prospectively in a computerized database.
RESULTS: The four groups included patients undergoing elective MVR with (n = 360) or without CABG (n = 1332) and urgent/emergent MVR with (n = 66) or without CABG (n = 86). Length of stay was significantly higher in patients undergoing elective MVR with CABG (15 days) than in those without CABG (11 days) but was not significantly different in patients undergoing urgent/emergent MVR with CABG (17 days) than in those without CABG (19 days). In-hospital mortality was significantly higher for patients undergoing elective (14%) or urgent/emergent (41%) MVR with CABG than in those undergoing MVR without CABG (elective:6%; urgent/emergent:20%). The 19-year survival rate was 32% for patients undergoing elective MVR with CABG compared with 51% for those without CABG and 28% for patients undergoing urgent/emergent MVR with CABG compared with 46% for those without CABG. Multivariate correlates of long-term mortality included older age, concomitant CABG, and urgent/emergent status. Hospital costs were significantly higher for patients undergoing elective MVR with ($33,216) than for those without ($23,890) CABG. No significant difference in cost were noted between patients undergoing urgent/emergent MVR with ($40,535) and without ($31,981) CABG.
CONCLUSIONS: The addition of CABG or urgent/emergent status to patients undergoing MVR significantly increases morbidity, mortality, and costs. Careful scrutiny of the benefits versus resource utilization is required for patients undergoing high risk MVR.

Entities:  

Mesh:

Year:  2000        PMID: 11016309     DOI: 10.1016/s0003-4975(00)01641-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Mitral repair is superior to replacement when associated with coronary artery disease.

Authors:  T Brett Reece; Curtis G Tribble; Peter I Ellman; Thomas S Maxey; Randall L Woodford; George M Dimeling; Harry A Wellons; Ivan K Crosby; John A Kern; Irving L Kron
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

2.  Minimally invasive surgery for valvular heart disease.

Authors:  Daniel G Cuadrado; Marzia Leacche; John G Byrne
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-12

3.  Does urgent or emergent status influence choice in mitral valve operations? An analysis of outcomes from the Virginia Cardiac Surgery Quality Initiative.

Authors:  Damien J LaPar; Sara Hennessy; Eddie Fonner; John A Kern; Irving L Kron; Gorav Ailawadi
Journal:  Ann Thorac Surg       Date:  2010-07       Impact factor: 4.330

4.  Combined PCI and minimally invasive heart valve surgery for high-risk patients.

Authors:  Ramanan Umakanthan; Marzia Leacche; Michael R Petracek; David X Zhao; John G Byrne
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-12

5.  Trend, predictors, and outcomes of combined mitral valve replacement and coronary artery bypass graft in patients with concomitant mitral valve and coronary artery disease: a National Inpatient Sample database analysis.

Authors:  Waqas Ullah; Sajjad Gul; Sameer Saleem; Mubbasher Ameer Syed; Muhammad Zia Khan; Salman Zahid; Abdul Mannan Khan Minhas; Salim S Virani; Mamas A Mamas; David L Fischman
Journal:  Eur Heart J Open       Date:  2022-01-13

6.  Sex differences in risks of in-hospital and late outcomes after cardiac surgery: a nationwide population-based cohort study.

Authors:  Feng-Cheng Chang; Shao-Wei Chen; Yi-Hsin Chan; Chia-Pin Lin; Victor Chien-Chia Wu; Yu-Ting Cheng; Dong-Yi Chen; Kuo-Chun Hung; Pao-Hsien Chu; An-Hsun Chou
Journal:  BMJ Open       Date:  2022-02-02       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.